USA flag logo/image

An Official Website of the United States Government

Search


Download to spreadsheetPrint
Displaying 51 – 75 of 9023 Awards
Company: AFASCI, INC. Agency/Program/Year/Phase: HHS / STTR / 2013 / 2
Abstract: … PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The aim of the present project is to develop an automated, noninvasive, high throughput and low lost sleep deprivation system for rodents. This system can help to study sleep loss impact on health and drug discovery… more
Company: AFASCI, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … be potential mechanisms underlying in vivo effects. The discovery of these lead TP compounds comes from the collaboration among Dr. Hua, a medicinal chemist, Dr. Jin, an AD neuropathology expert, and recently the PI Dr. Xie, who has substantial experience in pharmaceuticals… more
Company: AFASCI, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): Our completed SBIR Phase I project (R43 DA031578) was in response to NIH PA11-096, PHS 2011-02 'Omnibus solicitation for SBIR/STTR Grant Application' under NIDA 2, Development of Alternate Drug Delivery Dosage Forms for … more
Company: AFASCI, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: Under this Small Business Innovation Research (SBIR) Phase I project, Research Topic 149, the Contractor shall develop predictive in vivo screening systems for phenotypic drug discovery for smoking cessation. The Contractor shall accomplish this throughthe following… more
Company: Agave BioSystems, Inc. Agency/Program/Year/Phase: DOD / STTR / 2013 / 1
Abstract: Agave BioSystems, with their academic partners at the Mote Marine Laboratory, proposes to develop probiotic pharmaceuticals from indigenous commensal microbes to enhance gastrointestinal health in the bottlenose dolphin (Tursiops truncatus). The dolphin gastrointestinal… more
Company: Agave BioSystems, Inc. Agency/Program/Year/Phase: DOD / SBIR / 2013 / 2
Abstract: Wound management becomes increasingly challenging due to bacterial infections, especially from epidemic drug-resistant strains. To address this problem, Agave BioSystems proposes to develop a RANT (Rapidly Adaptable Nanotherapeutics) breadboard system built upon the modules… more
Company: AKONNI BIOSYSTEMS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: …. For every TB-infected white person in the United States, there are an estimated 9 African- Americans, 8 Latinos, 6 Native Americans, 23 Asians, and 21 Native Hawaiian/Pacific Islanders with this disease [2]. Compounded with this disparity is the prevalence of drug-resistant… more
Company: Radiation Monitoring Devices, Inc. Agency/Program/Year/Phase: DOE / SBIR / 2013 / 2
Abstract: … physics research, nuclear waste cleanup, nuclear treaty verification, geological exploration and development of new sources to effectively address our nations future energy needs. Proposed detectors will also permit scientific research enabling development of new drugs,… more
Company: ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): The goal of the proposed project is to develop a commercial kit that will allow drug addiction researchers with ongoing projects using cell-based models to be able to successfully and conveniently produce human inducedpluripotent stem cells… more
Company: VASCULOX, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: …d to warm ischemic times to mimic DCD kidneys can be rescued by treating the donor kidney and/or recipient with CD47humAb. 1B. Test the efficacy of the CD47humAb in an allogeneic (Brown Norway to Lewis) rat kidney transplant model with the use of an immunosuppressive drug… more
Company: AM BIOTECHNOLOGIES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …ts that rival the performance of the best biologically-produced antibodies. X-Aptamers will address almost all limitations associated with widely-used antibodies and have the potential to lead to more effective diagnostics as well as new classes of therapeutic drugs… more
Company: AM BIOTECHNOLOGIES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … RELEVANCE PUBLIC HEALTH RELEVANCE: Functional RNA molecules such as aptamers, miRNAs, and siRNAs have exciting potential as therapeutics in areas such as viral infections, cancer, genetic disorders, and neurological diseases. However, these potential RNA drugs require… more
Company: ANCORA PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: The glycosaminoglycan (GAG) class of carbohydrates is characterized by unparalleled sequence diversity. Located on the cell surface and in the extracellular matrix, specific structural features are required for a variety of functions including coagulation, cell-signaling and wound healing among… more
Company: APOGEE BIOTECHNOLOGY CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Radiation-induced production of pro-inflammatory and pro-fibrotic cytokines results in chronic and irreversible damage to the lungs. To date, no agent has demonstrated a sufficient safety profile to be utilized as a clinical drug for… more
Company: APPLIED BEHAVIORAL RESEARCH, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: DESCRIPTION (provided by applicant): ABR's recent series of innovative randomized trials evaluating the efficacy of various strategies for training clinicians to use evidence based therapies in alcohol and drug abuse has indicated that while both in-personworkshop and… more
Company: TRIA BIOSCIENCE CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …estimated 40-50 million people afflicted in the US alone. AIT provides long-term benefits for the patient and its need for optimization creates a compelling business opportunity. There is a very strong rationale to develop GLA for allergy based on its superior drug profile to… more
Company: APT THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …ntensity with time. Bone cancer pain is one of the most difficult of all persistent pains to control because the metastases are generally not limited to a single site and bone cancer pain is associated with unique pathophysiology. Nonsteroidal anti-inflammatory drugs (NSAIDs)… more
Company: ARADIGM CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …y of CFI and DRCFI in a mouse model of M. aviumor M. abscess us lung infection; and 4) to test the same regimen as Aim 3 for M. avium in a mouse model of M. avium disseminated infection. If an efficacious treatment with CFI or DRCFI (alone or in combination with other drugs) is… more
Company: ARADIGM CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …. One is well absorbed from the lungs and airways and excreted in urine. The other is not absorbed from the lungs and airways, but can be prepared in monodisperse insoluble particles. We accordingly propose to examine whether overnight oral administration of the first drug… more
Company: ARIETIS Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … recent meta-analysis of clinical data showed that treatment failure is 22%. An estimated 70% of failures are due to antibiotic resistance. Considering the total number of cases, treatment failure is very high, and H. pylori is emerging as one of the most significant … more
Company: ARMAGEN TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … disease or Parkinson's disease. The biologic TNF inhibitors (TNFI), such as the TNF decoyreceptor, cannot be developed for brain diseases, because the TNFIs are large molecules that do not cross the blood-brain barrier (BBB). The present work continues the drug… more
Company: ARMAGEN TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: … will develop a manufacturing plan that canbe replicated for future GMP manufacturing. The AGT-183 produced in phase II will be evaluated for safety, toxicology and pharmacokinetics in Rhesus monkeys. The completion of this work will enable entry of the AGT-183 drug development… more
Company: Thermally Targeted Therapeutics, Incorporated Agency/Program/Year/Phase: NSF / STTR / 2013 / 1
Abstract: … cancer stem cells, thereby boosting prevention of and lowering likelihood for cancer recurrence. Success in the proposed experiments would further indicate that this technology can be modified to achieve the targeted delivery of other highly specific anti-cancer drug that… more
Company: ATHERSYS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) represents a significant unmet medical need with over 1 million patients in the United States suffering from acute myocardial infarction (AMI) each year. This epidemic of heart attacks alsorepresents a risk factor for further… more
Company: ATHERSYS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 2
Abstract: …cal trials and novel therapeutic approaches for neurological injury. The specific objective of this SBIR Fast-Track Research Proposal is to define and successfully execute pivotal pre-clinical safety and efficacy studies required for a successful Investigational New Drug… more
Displaying 51 – 75 of 9023 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.